(MMSI) Merit Medical Systems - Overview
Stock: Catheters, Stents, Guidewires, Trays, Sensors
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 28.3% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.87 |
| Alpha | -38.63 |
| Character TTM | |
|---|---|
| Beta | 0.867 |
| Beta Downside | 1.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.38% |
| CAGR/Max DD | 0.20 |
Description: MMSI Merit Medical Systems January 09, 2026
Merit Medical Systems (NASDAQ:MMSI) designs, develops, manufactures, and markets single-use medical devices for interventional, diagnostic, and therapeutic procedures worldwide. The firm operates two primary segments-Cardiovascular and Endoscopy-and offers a broad portfolio that includes micropuncture kits, guide wires, embolotherapy and spine-intervention products, as well as custom procedural solutions such as critical-care trays, coating services, and MEMS sensor components. Sales are made to hospitals, ambulatory-care providers, and OEM partners through a mix of direct sales, distributors, and custom-tray manufacturers.
Key recent metrics: FY 2023 revenue reached approximately $1.2 billion, up about 8 % year-over-year, driven by strong demand for minimally invasive cardiovascular tools and a 12 % increase in endoscopy product shipments. The company’s operating margin expanded to 13 % as it leveraged higher-margin custom-solution contracts. Sector-wide, the U.S. interventional-procedure market is projected to grow at a 5-6 % CAGR through 2028, supported by an aging population and a shift toward outpatient care-both tailwinds for Merit’s single-use device model.
For a deeper, data-driven look at how Merit Medical’s fundamentals stack up against peers, you might explore the analytics platform ValueRay for additional insight.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 118.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.86 > 1.0 |
| NWC/Revenue: 51.12% < 20% (prev 66.22%; Δ -15.11% < -1%) |
| CFO/TA 0.10 > 3% & CFO 267.6m > Net Income 118.4m |
| Net Debt (428.7m) to EBITDA (313.0m): 1.37 < 3 |
| Current Ratio: 4.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.9m) vs 12m ago 0.64% < -2% |
| Gross Margin: 48.47% > 18% (prev 0.46%; Δ 4801 % > 0.5%) |
| Asset Turnover: 58.98% > 50% (prev 55.70%; Δ 3.28% > 0%) |
| Interest Coverage Ratio: 6.45 > 6 (EBITDA TTM 313.0m / Interest Expense TTM 28.1m) |
Altman Z'' 4.80
| A: 0.29 (Total Current Assets 985.5m - Total Current Liabilities 230.5m) / Total Assets 2.63b |
| B: 0.30 (Retained Earnings 786.0m / Total Assets 2.63b) |
| C: 0.07 (EBIT TTM 181.1m / Avg Total Assets 2.50b) |
| D: 1.39 (Book Value of Equity 1.53b / Total Liabilities 1.10b) |
| Altman-Z'' Score: 4.80 = AA |
Beneish M -2.94
| DSRI: 0.97 (Receivables 231.5m/213.3m, Revenue 1.48b/1.32b) |
| GMI: 0.94 (GM 48.47% / 45.71%) |
| AQI: 1.22 (AQ_t 0.43 / AQ_t-1 0.35) |
| SGI: 1.12 (Revenue 1.48b / 1.32b) |
| TATA: -0.06 (NI 118.4m - CFO 267.6m) / TA 2.63b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of MMSI shares?
Over the past week, the price has changed by +1.74%, over one month by -11.33%, over three months by -4.64% and over the past year by -24.35%.
Is MMSI a buy, sell or hold?
- StrongBuy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MMSI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104 | 26.1% |
| Analysts Target Price | 104 | 26.1% |
| ValueRay Target Price | 78.7 | -4.6% |
MMSI Fundamental Data Overview February 05, 2026
P/E Forward = 20.3252
P/S = 3.2308
P/B = 3.12
P/EG = 1.6936
Revenue TTM = 1.48b USD
EBIT TTM = 181.1m USD
EBITDA TTM = 313.0m USD
Long Term Debt = 732.9m USD (from longTermDebt, last quarter)
Short Term Debt = 10.6m USD (from shortTermDebt, last quarter)
Debt = 821.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 428.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.20b USD (4.77b + Debt 821.2m - CCE 392.5m)
Interest Coverage Ratio = 6.45 (Ebit TTM 181.1m / Interest Expense TTM 28.1m)
EV/FCF = 21.68x (Enterprise Value 5.20b / FCF TTM 239.9m)
FCF Yield = 4.61% (FCF TTM 239.9m / Enterprise Value 5.20b)
FCF Margin = 16.24% (FCF TTM 239.9m / Revenue TTM 1.48b)
Net Margin = 8.02% (Net Income TTM 118.4m / Revenue TTM 1.48b)
Gross Margin = 48.47% ((Revenue TTM 1.48b - Cost of Revenue TTM 761.2m) / Revenue TTM)
Gross Margin QoQ = 48.52% (prev 48.24%)
Tobins Q-Ratio = 1.98 (Enterprise Value 5.20b / Total Assets 2.63b)
Interest Expense / Debt = 0.82% (Interest Expense 6.75m / Debt 821.2m)
Taxrate = 27.98% (10.8m / 38.5m)
NOPAT = 130.4m (EBIT 181.1m * (1 - 27.98%))
Current Ratio = 4.28 (Total Current Assets 985.5m / Total Current Liabilities 230.5m)
Debt / Equity = 0.54 (Debt 821.2m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = 1.37 (Net Debt 428.7m / EBITDA 313.0m)
Debt / FCF = 1.79 (Net Debt 428.7m / FCF TTM 239.9m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.73% (Net Income 118.4m / Total Assets 2.63b)
RoE = 8.13% (Net Income TTM 118.4m / Total Stockholder Equity 1.46b)
RoCE = 8.27% (EBIT 181.1m / Capital Employed (Equity 1.46b + L.T.Debt 732.9m))
RoIC = 5.96% (NOPAT 130.4m / Invested Capital 2.19b)
WACC = 7.86% (E(4.77b)/V(5.59b) * Re(9.11%) + D(821.2m)/V(5.59b) * Rd(0.82%) * (1-Tc(0.28)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.31%
[DCF Debug] Terminal Value 81.72% ; FCFF base≈213.0m ; Y1≈262.8m ; Y5≈447.5m
Fair Price DCF = 124.1 (EV 7.78b - Net Debt 428.7m = Equity 7.36b / Shares 59.3m; r=7.86% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 0.22 | EPS CAGR: -41.83% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 8.96% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.89 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=9
EPS next Year (2026-12-31): EPS=4.05 | Chg30d=+0.034 | Revisions Net=+1 | Growth EPS=+8.2% | Growth Revenue=+6.2%